Individualized Incremental Hemodialysis Study

Summary

Thrice weekly hemodialysis has been the standard of care all-over the world for end-stage renal disease (ESRD) requiring renal replacement therapy (RRT). Despite being in the era of precision medicine and individualized healthcare, this program doesn't take into account patients with residual kidney function (RKF) who don't require a thrice weekly hemodialysis frequency. Incremental hemodialysis (defined as twice weekly hemodialysis initiation in incident hemodialysis patients with residual kidney function) has been raised as an alternative to the conventional thrice weekly dialysis. Retrospective trials has proved safety of a twice weekly initiation with comparative efficacy to the thrice weekly program. Despite that, there is paucity of prospective observational and rarity of randomized controlled trials comparing both regimens. In this study, the investigators tend to provide a more individualized incremental hemodialysis approach to incident hemodialysis patients with residual urine volume and RKF. The investigators will compare the results to ESRD patients initiating a thrice weekly hemodialysis program.

Conditions

• Hemodialysis Complication
• ESRD
• Renal Failure

Interventions

PROCEDURE

Individualized Incremental hemodialysis

Individualized Incremental hemodialysis program (twice/week, once/week, once/10days or less frequent) will be provided to incident ESRD patients according to their symptom presentation, clinical examination, investigations and daily urine volume measurement.

PROCEDURE

Conventional thrice weekly hemodialysis

Thrice weekly hemodialysis program, the current standard of care for all patients, as a control

Sponsors & Collaborators

• Kidney and urology Center

  collaborator UNKNOWN

• Mansoura University

  collaborator OTHER

• Fasila Hemodialysis Center

  collaborator UNKNOWN

• Alexandria University

  lead OTHER

Principal Investigators

• Mohamed E Elrggal, MD · Alexandria University

• Mohamed A Sobh, MD · Mansoura University

• Hussein A Sheashaa, MD · Mansoura University

• Ahmed F Elkeraie, MD · Alexandria University

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2017-06-01

Primary Completion

2020-09-01

Completion

2020-12-01

Countries

• Egypt

Study Locations